FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS
Neurology News Network for the week of September 22, 2018.
Pharyngeal Electrical Stimulation Increases Proportion of Patients Prepared for Decannulation
While PES has been debated as a successful therapy for post-stroke dysphagia, recent data has suggested it may be efficacious.
Eugenia Trushina, PhD: Communication and Learning Through Collaboration
For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.
PET Tracer Discriminates Alzheimer Disease From Other Neurodegenerative Disorders
The accuracy and potential utility of the [18F]flortaucipir tracer in patient care will require further research in clinically more representative populations.
Paul Newhouse, MD: Exploring VU319 in Alzheimer Disease
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
Treating Sleep Apnea Significantly Improves Stroke Neurological Symptoms, Functional Status
Patients with stroke should receive screening for sleep apnea in the short-term event period, receiving treatment with continuous positive airway pressure.
Addressing Augmentation in Restless Leg Syndrome
The RLS expert explained his best practices for treating patients who develop augmentation after treatment.
Case Report: Two Days of Intermittent Dizziness and Tingling in the Right Arm and Leg
A 64-year-old man, who has been a smoker for 40 years, presents at urgent care with dizziness, persistent hiccups, and dizziness. What's your diagnosis?
Pediatric Epilepsy, a Heterogeneous Disorder
The associate chief of clinical pediatric neurology, director of the pediatric neurophysiology lab, and director at the Adolescent Epilepsy Center at UCLA spoke about therapeutic options for pediatric epilepsy.
Howard Fillit, MD: Emphasizing Care in Alzheimer Disease
With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.
A Turning Point for Pediatric Epilepsy
M. Scott Perry, MD, spoke about the industry's excitement surrounding the current treatment landscape for pediatric epilepsy.
Biomarker Research Required to Further Advance Alzheimer Drug Discovery
Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.
Ronald Crystal, MD: Introducing Genetics into Alzheimer Disease
Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?
Eugenia Trushina, PhD: Mitochondria as a Therapeutic Target for Alzheimer
The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.
Patricia Coyle, MD: Multiple Sclerosis Symptom Management
Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.
Staying Knowledgeable, Reducing Stigma of Pediatric Epilepsy
The Medical Director of Neurology and Justin Neurosciences Center at Cook Children's Medical Center spoke about the importance of staying up-to-date and informed about this rapidly changing space.
Guideline Update: Disorders of Consciousness
Practice guidelines for the management of low-level, minimally conscious states resulting from brain injury include recommendations for assessment, treatment protocol, and supportive approaches.
Howard Fillit, MD: Alzheimer Disease Drug Development Improvement
The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.
Allogeneic Mesenchymal Stem Cells Under Exploration for Alzheimer Disease, Aging Frailty
Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.
Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.
For Mild Cognitive Impairment, Behavioral Activation Outperforms Supportive Therapy
Memory decline was worse for patients with MCI receiving supportive therapy over behavioral activation.
Treating and Identifying Large Vessel Occlusion Quickly
The assistant professor of neurology and neurosurgery spoke about the need to identify LVO in the field, quickly, to improve care.
Patricia Coyle, MD: Needed Improvements in Multiple Sclerosis
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.
XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success
Neurology News Network for the week of September 15, 2018.
Communication and Cooperation in Epilepsy Care
The director of the Epilepsy Program at the Banner University Medical Center spoke about the importance of interaction between general neurology and epileptologists.
FDA Approves Fremanezumab for Migraine Prevention
The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.
Biohaven Submits IND for Migraine Therapy BHV-3500
The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.
Pediatric Epilepsy, Treating the Whole Patient
Jason Lerner MD, discussed the recently opened Adolescent Epilepsy Center at UCLA, a clinic that offers comprehensive care for teens with epilepsy.
Phase II Trial of Trans Sodium Crocetinate in Acute Stroke Endorsed by FDA
TSC has shown potential to become the first approved therapy for acute stroke, able to be administered in the ambulance.
Fingolimod Lowers Relapse Rates, MRI Lesion Accumulation in Pediatric Patients
After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.
